[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563853":3},{"organization":4,"armGroups":7,"interventions":35,"overallOfficials":41,"centralContacts":62,"locations":68,"responsibleParty":81,"collaborators":41,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":85,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":41,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":105,"overallStatus":71,"whyStopped":41,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Hansoh BioMedical R&D Company","INDUSTRY",[8,14,18,23,27,31],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1a","EXPERIMENTAL","NSCLC",[13],"Drug: HS-20117 combined Platinum-containing chemotherapy",{"label":15,"type":10,"description":11,"interventionNames":16},"Cohort 2a",[17],"Drug: HS-20117 combined HS-20093",{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3a","CRC",[22],"Drug: HS-20117+CAPEOX",{"label":24,"type":10,"description":20,"interventionNames":25},"Cohort 4a",[26],"Drug: HS-20117+FOLFIRI",{"label":28,"type":10,"description":20,"interventionNames":29},"Cohort 5a",[30],"Drug: HS-20117+mFOLFOX6",{"label":32,"type":10,"description":20,"interventionNames":33},"Cohort 6a",[34],"Drug: HS-20117 combined HS-20093 and 5-FU",[36,42,46,50,54,58],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"DRUG","HS-20117 combined HS-20093","HS-20117 + HS-20093",[15],null,{"type":37,"name":43,"description":44,"armGroupLabels":45,"otherNames":41},"HS-20117 combined Platinum-containing chemotherapy","HS-20117 + cisplatin\u002Fcarboplatin + pemetrexed",[9],{"type":37,"name":47,"description":48,"armGroupLabels":49,"otherNames":41},"HS-20117 combined HS-20093 and 5-FU","HS-20117 + HS-20093 + 5-FU",[32],{"type":37,"name":51,"description":52,"armGroupLabels":53,"otherNames":41},"HS-20117+CAPEOX","CAPOEX: Oxaliplatin+Capecitabine",[19],{"type":37,"name":55,"description":56,"armGroupLabels":57,"otherNames":41},"HS-20117+FOLFIRI","FOLFIRI=Irinotecan+Leucovorin Calcium+5-FU",[24],{"type":37,"name":59,"description":60,"armGroupLabels":61,"otherNames":41},"HS-20117+mFOLFOX6","mFOLFOX6=Oxaliplatin+Leucovorin Calcium+5-FU",[28],[63],{"name":64,"role":65,"phone":66,"phoneExt":41,"email":67},"Xiaowei Yan","CONTACT","13061877102","yanxw@hspharm.com",[69],{"facility":70,"status":71,"city":72,"state":41,"zip":41,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":41},"Tianjin Medical University Cancer Institute & Hospital","RECRUITING","Tianjin","China","CN",{"type":76,"coordinates":77},"Point",[78,79],117.17667,39.14222,{"lat":79,"lon":78},{"type":82,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR","100563853","phase-1-phase-ib-trial-of-hs-20117-in-combination-with-other-drugs-in-advanced-solid-tumors-100563853",false,"NCT06621563","Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors","Safety, Tolerability, Efficacy, Pharmacokinetics Profile and Immunogenicity of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors, a Phase Ib Clinical Trial","HS-20117","Inclusion Criteria:\n\n* Males or females aged 18 - 75 years (inclusive).\n* Histologically confirmed unresectable, recurrent or metastatic solid tumors.\n* At least one target lesion per the RECIST v1.1.\n* ECOG performance status of 0-1.\n* Minimum life expectancy \\> 12 weeks.\n* Males or Females should be using adequate contraceptive measures throughout the study.\n* Females must not be pregnant at screening or have evidence of non-childbearing potential.\n* Signed Informed Consent Form.\n\nExclusion Criteria:\n\n* Received or are receiving the following treatments:\n\n  1. Any anticancer therapy targeting MET, including TKIs, antibodies or antibody-drug conjugates.\n  2. Monoclonalor bispecific antibodies targeting EGFR.\n  3. Systemic anti-cancer treatment (Cytotoxicities and anti-cancer Traditional Chinese medicine or TKIs) within 2 weeks prior to the first dose of HS-20117.\n  4. Investigational anti-cancer drugs or antibodies or ADCs within 4 weeks prior to the first dose of HS-20117.\n  5. Local radiotherapy within 2 weeks prior to the first dose of HS-20117, more than 30% of bone marrow irradiation or large-area radiotherapy within 4 weeks before the first dose of HS-20117.\n  6. Presence of pleural effusion\u002Fascites requiring clinical intervention; presence of pericardial effusion.\n  7. Major surgery within 4 weeks prior to the first dose of HS-20117.\n* Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy.\n* Presence of uncured secondary primary malignancies.\n* Untreated, or active central nervous system metastases.\n* Severe, uncontrolled or active cardiovascular disorders.\n* Serious infection within 4 weeks prior to the first dose of HS-20117.","ALL","18 Years","75 Years",{"count":95,"type":96},780,"ESTIMATED","INTERVENTIONAL",[99],"PHASE1","HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid tumors.",[102,103,104],"Solid Tumors","Non-Small Cell Lung Cancer","Colorectal Cancer",[106,107,108,109],"Solid tumor","EGFR\u002Fc-MET bispecific antibody","B7H3 ADC","chemotherapy","2025-04-07",{"date":112,"type":113},"2025-04-09","ACTUAL",{"date":115,"type":113},"2024-12-14",{"date":117,"type":96},"2026-12-01",{"name":5,"class":6},1]